



This is an English translation of a Hebrew immediate report that was published on December 25 2022 (Ref No.: 2022-01-154663) (hereafter: the “**Hebrew Version**”). This English version is only for convenience purposes. This is not an official translation and has no binding force. Whilst reasonable care and skill have been exercised in the preparation hereof, no translation can ever perfectly reflect the Hebrew Version. In the event of any discrepancy between the Hebrew Version and this translation, the Hebrew Version shall prevail.

BEEIO HONEY LTD

(the "Company")

December 25, 2022

Attn.

Israel Securities Authority www.isa.gov.il
Tel Aviv Stock Exchange Ltd www.tase.co.il

Dear Sirs and Madams,

Re: The company has successfully completed a comprehensive self-examination for compliance of all ingredients of a cultivated honey product developed by the company intended for the U.S market, with the requirements of the U.S. Food and Drug Administration (FDA)

The company is honored to inform its shareholders that on December 24, 2022, Beeio Honey Technologies Ltd., a private company fully owned by the company (the "**Subsidiary**"), announced it successfully completed a comprehensive self-examination, which was conducted with the assistance of an American law firm specializing in food regulation in the USA, of all the ingredients of a cultivated honey product the company developed, that is intended to be marketed as a food product, in the American market ¹ (the "**Product**"). More specifically, the company describes the Product as a cultivated honey product produced without bees in a process that combines nectar components from plants and proteins manufactured via precision fermentation that mimic the function of enzymes in the stomach of a bee.

The conclusion of the company's self-examination, which the American law firm agreed with, was that all the product ingredients are lawful and permitted for use in food under the United

¹ The company's examination only considered the regulatory status of the ingredients Bee-io plans to intentionally add to its Product. Bee-io will separately ensure its final Product is otherwise compliant with U.S. food laws, including product naming and labeling regulations.



States Federal Food, Drug and Cosmetic Act (FDCA) and its implementing regulations when used to manufacture the Product².

The Company's self-determination that all ingredients intentionally used to produce its cultivated honey product comply with FDA requirements serves as an important basis, among other factors, to facilitate the lawful marketing of cultivated honey in the U.S. market.

The information mentioned in this notice is “Forward Looking Statement” as defined in The Securities Act, 5728-1968, based on the information known to the Company as of this date, and on estimates and predictions which their realization depends, among others, on factors that are outside of the Company’s control. It is noted that the Company is a research and development company and as such, its estimations might be realized in a different manner, if at all, given that the Company’s Technology is preliminary and precedential.

Sincerely,
OFIR DVASH, CEO
BEEIO HONEY LTD.

² The company's conclusions assume that the specific regulatory requirements for certain ingredients will be met and that the company will purchase certain raw materials from suppliers with appropriate regulatory status.